Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2005-11-10
2011-10-18
Canella, Karen (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S155100, C424S172100, C424S174100, C424S178100
Reexamination Certificate
active
08038998
ABSTRACT:
Improved methods for treatment of cancer which involve the targeting of slow-growing, relatively mutationally-spared cancer stem line are provided. These methods are an improvement over previous cancer therapeutic methods because they provide for very early cancer treatment and reduce the likelihood of clinical relapse after treatment.
REFERENCES:
patent: 4894326 (1990-01-01), Matsuura
patent: 5169835 (1992-12-01), Chan
patent: 5300500 (1994-04-01), Lee
patent: 5489516 (1996-02-01), Broudy et al.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5587458 (1996-12-01), King
patent: 5688657 (1997-11-01), Tsang
patent: 5730982 (1998-03-01), Scheinberg
patent: 5808002 (1998-09-01), Buhring
patent: 5843633 (1998-12-01), Yin et al.
patent: 5869045 (1999-02-01), Hellstrom et al.
patent: 5877299 (1999-03-01), Thomas et al.
patent: 5942602 (1999-08-01), Wels et al.
patent: 5990281 (1999-11-01), de Sauvage et al.
patent: 6004528 (1999-12-01), Bergstein
patent: 6129915 (2000-10-01), Wels et al.
patent: 6258939 (2001-07-01), Reiter et al.
patent: 6506881 (2003-01-01), Adair et al.
patent: 7361336 (2008-04-01), Bergstein
patent: 7427400 (2008-09-01), Bergstein
patent: 7504103 (2009-03-01), Bergstein
patent: 7608259 (2009-10-01), Bergstein
patent: 2001/0055751 (2001-12-01), Reiter et al.
patent: 2007/0036800 (2007-02-01), Bergstein
patent: 2007/0036801 (2007-02-01), Bergstein
patent: 2007/0036802 (2007-02-01), Bergstein
patent: 2007/0036803 (2007-02-01), Bergstein
patent: 2007/0036804 (2007-02-01), Bergstein
patent: 2007/0041984 (2007-02-01), Bergstein
patent: 2008/0305107 (2008-12-01), Bergstein
patent: 2009/0011441 (2009-01-01), Bergstein
patent: 2009/0022740 (2009-01-01), Bergstein
patent: 2009/0022741 (2009-01-01), Bergstein
patent: 2009/0028878 (2009-01-01), Bergstein
patent: 2009/0028879 (2009-01-01), Bergstein
patent: WO 90/12885 (1990-11-01), None
patent: WO 94/07474 (1994-04-01), None
patent: WO 95/07348 (1995-03-01), None
patent: WO95/30439 (1995-11-01), None
The abstract of Tanaka et al (Nihon Igaku Hoshasen Gakkai zasshi. Nippon acta radiologica, 1996, vol. 13, pp. 967-973).
The abstract of Peters et al (Blut, 1988, vol. 57, pp. 91-95).
Watt et al, Phil Trans Soc London, B, 1998, vol. 353, pp. 831-837.
Sigel et al (American Joural of Physiology, 1992, vol. 263, pp. G139-G148).
Gels et al, Annals of Oncology, 1997, vol. 4, pp. 321-327).
Bui et al (Cancer and Metastasis Reviews, Dec. 1998, vol. 17, pp. 391-399).
Berezovska et al. (Abstract) Annals of the NY Academy of Sciences, 200, vol. 921, pp. 223-226.
Bonnet and Dick (1997). Nature Medicine 3: 730-737.
Boucher, et al., 1995, The expression of trophoblasic cell markers by lung carcinomas, Human Pathology, vol. 26, pp. 1201-1206.
Chen, et al. Blood, 1997, vol. 89, pp. 3345-3353.
Door, Int. Journal of Radiation Biology, 1997, vol. 72, pp. 635-643.
Eck, et al. Gene-Based Therapy, In: The Pharmacological Basis of Therapeutics, Goodman nd Gilman, Ed.s. 1996, pp. 77-10.
Haynes, et al. Virchows Arch, 1985, vol. 405, pp. 263-275.
Heikinheimo, et al. Blood, 1987, vol. 70, pp. 1279-1283.
Hope et al. archives of Med. Res. 34: 507-514, 2003.
Lin H., Schagat T. Neuroblasts: a model for the asymmetric divison of stem cells. Trends in Genetics 13: 33-39, 1997.
Metcalf, Hematology and Blood Transfusion, vol. 28, pp. 320-326, 1983.
Miraglia et al. Blood, vol. 90, pp. 5013, 5021, 1997.
Miyamura, et al. (Abstract) Sapporo Igaku Zasshi, 1991, vol. 60, pp. 183-185.
Mizutani. (Abstract) Sapporo Medical Journal, 1990, vol. 59, pp. 345-356.
Moroz, et al. Pure and Applied Chemistry, 1993, vol. 65, pp. 1253-1264.
O'Brien and Morrow. Recent Clinical Developments in Gynecologic Oncology, Paul Morrow et al., Ed.s. pp. 167-180, 1983.
Orkin et al. Report and Recommendation of the Pan to Assess the NIH Investment in Research on Gene Therapy. NIH, 1995.
Otto. Int. J. Exp. Path., 78: 291-310, 1997.
Passegue, et al. Proc. Natl. Acad. Sci. U.S.A. 100: 11842-11849, 2003.
Rooney et al. Gene, vol. 71, pp. 439-449, 1988.
Sachs. Cancer, vol. 67, pp. 2684-2694, 1991.
Sakakibara et al. Mouse Musashi1, a neural RNA-binding protein highly enriched in the mammalian CNS stem cell line. Developmental biology, vol. 176, pp. 230-242, Jun. 1996.
Schlom, In: Molecular foundations of Oncology, Samuel Broder, Ed. 1991, pp. 95-134.
Shtalrid et al. European Journal of Hematology, 1987, vol. 38, pp. 3-11.
Sherley et al. PNAS, vol. 92, pp. 136-140, 1995.
Stedman's Medial Dictionary, 27th Edition, 1995.
Taichman, et al. (Abstract) Developmental Dynamics, vol. 225, pp. 166-175, 2002.
Ten Have-Opbroek Aaw, et al. In favour of an oncofetal concept of bronchogenic carcinoma development. Histol Histopathol 9: 375-384, 1994.
Ten Have-Opbroek Aaw, et al. The alveolar type II cell is a pluripotential stem cell in the genesis of human adenocarcinomas and squamous cell carcinomas. Histol Histopathol 12: 319-336, 1997.
Verma, et al. Nature, vol. 389, pp. 239-242, 1997.
Notice of Allowance in file history of U.S. Appl. No. 09/468,286, filed Dec. 20, 1999.
Notice of Allowance in file history of U.S. Appl. No. 11/583,841, filed Oct. 18, 2006.
Notice of Allowance in file history of U.S. Appl. No. 11/583,857, filed Oct. 18, 2006.
Nicholson et al., “Radioimmunotherapy after chemotherapy compared to chemotherapy alone in the treatment of advanced ovarian cancer: a matched analysis,” Oncol. Rep., 1998, 5(1):223-226.
Moseley et al., “Carcinomatous meningitis: antibody-guided therapy with I-131 HMFG1 ,” J. Neurol. Neurosurg. and Psych., 1991, 54:260-265.
Schrier et al., “High dose 90Y Mx-diethylenetriaminepentaacetic acid (DTPA)-BrE-3 and autologous hematopoietic stem cell support (AHSCS) for the treatment of advanced breast cancer: a phase I trial,” Cancer Res. (Suppl.), 1995, 55:5921s-5924s.
Denardo et al., “Radioimmunotherapy for breast cancer using indium-111/yttrium-90 BrE-3: Results of a phase I clinical trial,” J. Nuclear Med., 1997, 38(8):1180-1185.
Riethmuller et at., “Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group,” Lancet, 1994, 343(8907):1 177-1183.
Weiner et al., “Phase II multicenter evaluation of prolonged murine monoclonal antibody 17-1A therapy in pancreatic carcinoma,” J. Immunother Emphasis Tumor Immunol., 1993, 13(2):110-116.
Ragnhammar et al., “Effect of monoclonal antibody 17-1A and GM-CSF in patients with advanced colorectal carcinoma- long-lasting, complete remissions can be induced,” Int. J. Cancer, 1993, 53:751-758.
Hempel et al., “Transplantation of ex vivo tumor cell purged PBSCT in breast cancer patients treated with high dose chemotherapy followed by supplementary immunotherapy with MOAB 17-1-A phase I study,” Abstract No. 554 at the 1998 ASCO Annual Meeting.
Baselga et al., “Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2
eu-overexpressing metastatic breast cancer,” Semin. Oncol., 1999, 26(4 Suppl. 12):78-83.
Baselga et al., “Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2
eu-overexpressing metastatic breast cancer,” J. Clin. Oncol., 1996, 14(3):737-744.
Pegram et al., “Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2
eu monoclonal antibody plus cisplatin in patients with HER2
eu-overexpressing metastatic breast cancer refractory to chemotherapy treatment,” J. Clin. Oncol., 1998, 16(8):2659-2671.
Cobleigh et al., “Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease,” J. Clin. Oncol., 1999, 17(9):2639-2648.
Baselga et al., “Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin,” J. Clin. Oncol., 2000, 18(4):904-914.
Bos et al.,
Canella Karen
Jones Day
LandOfFree
Methods of cancer therapy targeted against a cancer stemline does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of cancer therapy targeted against a cancer stemline, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of cancer therapy targeted against a cancer stemline will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4292291